Category Archives: Incorporation by Reference

DC decision of infringement and no invalidity of Pharmacyclic’s BTK inhibitor-related patents affirmed

Pharmacyclics LLC, Jannsen Biotech, Inc. v. Alvogen, Inc., Natco Pharma Limited Docket No. 2021-2270 ( (Non-Precedential) CHEN, BRYSON, HUGHES November 15, 2022 Brief Summary:   DC decisions that Pharmacyclic’s patents were infringed and not invalid for lack of written description, … Continue reading

Posted in Anticipation (35 USC 102), Double Patenting, Enablement, Generics / ANDA, Incorporation by Reference, Infringement, Method claims, Obviousness, Obviousness (Secondary Considerations), Priority, Public Accessibility, Written description | Leave a comment

DC claim construction based on definition incorporated-by-reference reversed

Finjan LLC v. ESET, LLC, ESET SPOL. S.R.O. Docket No. 2021-2093 ( PROST, REYNA, TARANTO November 1, 2022 Brief Summary:   DC grant of SJ of invalidity for indefiniteness based on claim construction relating to incorporation-by-reference reversed. Summary:  Finjan appealed … Continue reading

Posted in Claim Construction, Incorporation by Reference, Summary Judgment | Leave a comment

DC grant of SJ for indefiniteness and obviousness of Immunogen’s claims vacated and remanded

Immunogen, Inc. v. USPTO Docket No. 2021-1939 ( (Non-precedential) NEWMAN, CLEVENGER, STOLL March 25, 2022 Brief Summary:   DC grant of SJ that Immunogen’s pending claims are indefinite and obvious vacated and remanded as factual findings not undisputed. Summary:  Immunogen … Continue reading

Posted in Appeal, Incorporation by Reference, Indefiniteness, Obviousness, Written description | Leave a comment